This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Rising Pharmaceuticals to enter deferred prosecution agreement over generic drug price-fixing

( December 3, 2019, 21:43 GMT | Official Statement) -- MLex Summary: Rising Pharmaceuticals will enter a deferred prosecution agreement with the US Department of Justice over charges that it fixed prices on generic Benazepril HCTZ, a medicine used to treat hypertension, the agency said. Rising will pay a $1.5 million penalty as well as $1.1 million in civil damages for False Claims Act violations, the DOJ said.Statement follows below:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections